to view your mail
U.S. markets closed
Revive Therapeutics Ltd. (RVV.CN)
Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
At close: 3:59PM EST
6,618 reactions on $RVV.CN conversation
Sign in to post a message.
So WSJ online still listing a target of 2.36 and their analyst rates it a Buy. Yes, it listed it that way months ago and has possibly just not updated the site. So, one has to ask: has Revive lost strength as a company since then? No, if anything it is in a much stronger position. I liked it then. I like it now more. Yes, the red numbers hurt, but I'll wait.
Well since the CEO just purchased a ton of shares this past week I had zero issues with the pulling the trigger on this one. I can't see a downside since the share price is similar to the level the CEO just bought at. Good luck everyone.
Buy the dips and hold your shares. We have a real winner here. We just have to be patient.
Just so there is no doubt, CEO.ca lists the insider buys/sells/holdings quite clearly, and it is right there for you to see that CEO Michael Frank owns 1,946,500 shares, and that he bought 270,000 of these just this week on the open market. For some reason 70,000 of this 270,000 were not added to his holdings (if you check the sum total holdings on the right after each transaction), and I don't know why this is, but even without those, there were 200,000 added to his holdings this week. Thanks to M. here who put me onto CEO.ca - I'd ben using the much clunkier SEDI site.
Without a doubt, news will be released this week. We are still waiting on 4 trial updates before the end of Q1.
I could be misreading the situation but it feels like there is a lot of subtle signaling going on here from MF and Revive. They cannot officially disclose the efficacy results on Bucillamine yet, however a number of recent actions, updates and disclosures heavily hint that the company is messaging to the market to hang in there, positive results are coming. You have MF purchasing shares on the public market, the investor deck updated with lots of focus on Bucillamine, a Twitter campaign with big pharma hashtags, massive ramp up of the number of sites participating in the Bucillamine trials, etc. I feel like they are trying to scream as loud as they ethically and legally can that very positive news is coming. Unfortunately, I think the (mis-)communication around interim efficacy results had a lot people expecting an efficacy update last month which never materialized and that is one of the big reasons for the recent downward price pressure on this stock. Markets are all about expectations and where you land relative to them. I'm still personally very optimistic and holding long on RVV!
While the Bucillamine efficacy results are only known to the Independent Data and Safety Monitoring Board (“DSMB”) at this time, I believe they are solely responsible for recommendations on continuation, stopping or changes to the conduct of the study, Given that we're growing from 14 to 50 clinical sites, the DSMB would have almost certainly been seeing very positive outcomes in the study to-date to recommend this rapid rate of expansion. While it could be argued that they may have recommended the site increase because the results to date are not statistically significant to draw conclusions (Bucillamine vs placebo), I would imagine even a modest 1.5x of sites would have remedied that. But a more than 3.5x increase signals (to me at least) that results so far are promising and that the study should be expedited.
Michael Frank, CEO of Revive has purchased 100,000 shares since March 2nd. Just 4 days after their update on the FDA phase 3 clinical trial!
The fact that he keeps adding to his position should tell you something!
The original tweet is here:
Follow me on Twitter for more updates on RVV etc.
Michael frank bought another 170k shares yesterday, He has bought 270k shares over the past 3 days.
That's $112,225 CAD
someone here said psilocybin will have a much huger market than cannabis! wow! imagine that? i think it is absolutely possible because the benefits of psilocybin are far greater than that of cannabis!
Very excited for the future of Revive, smart money lives here and the CEO is brilliant, not to mention heavily invested. Holding long, investment stock.
Another 60k shares purchased by MF today, totaling 100k shares in 2 days. I think a great sign that he believes the shares to be undervalued.
CEO Michael Frank this week buying 270k shares
Well if anybody needs more confidence in this stock. The CEO purchased 40k shares today from the open market.
There it is at SEDI, Michael Frank, CEO of Revive, buying another 40,000 shares at market price ... he ought to know what is good and what is coming (and that dip in SP when the whole sector is dipping? nice try, bashers).
Texas opens 100% next week. How about we tag Abbot& Cruz and officials to let them know about RVV testing sites in Houston! Get this thing fast tracked and go boom! Just a thought! Happy Friday longs.
man I wish I had more cash to buy more shares rn!
Michael Frank purchases another 100,000 shares on the 4th of March.
I know we are expecting several news releases this month, but we need one of them soon to stop the bleeding. It's hard to watch. I need to stop watching for a few weeks. Easy to say, but hard to do LOL.
Was doing my research on sedar and came across the estimated cost to complete bucillamine trial, psilocybin based formulation, & cbd for AIH. Estimated cost they will spend in 2021 for buccillamine: 25,000,000
psilocybin based formulations: 500,000
cbd human clinical study:200,000.
Revive knows how buccillamine will play out, if they werent confident i doubt the company would drop 25 million to complete the trials. Ladies and gentlemen, were sitting on a gold mine.
Psilocybin could be the key to healing a WIDE variety of depression types.
Vanessa EDL Edits
MacKenzie Scott marries Seattle teacher after Bezos divorce
Nearly 3 million women have left labor force since COVID-19 began: Indeed study
Yahoo Finance Video
Suze Orman: Something's ‘radically wrong’ if you’re getting a tax refund
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research